# OnCo record nct07529782 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07529782/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07529782", "NCT07529782" ;
  schema:name "Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma"@en ;
  schema:description "A phase 1 trial of Pamlectabart tismanitin run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07529782/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07529782> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:drugs <https://onco.cc/drugs/pamlectabart-tismanitin/> ;
  onco:companies <https://onco.cc/companies/heidelberg-pharma/> .